| Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI osimertinib: conventional ways and immune checkpoint inhibitors L Wu, L Ke, Z Zhang, J Yu, X Meng Frontiers in Oncology 10, 602762, 2020 | 87 | 2020 |
| From inflammatory reactions to neurotransmitter changes: Implications for understanding the neurobehavioral changes in mice chronically infected with Toxoplasma gondii T Wang, X Sun, W Qin, X Zhang, L Wu, Y Li, C Zhou, H Zhou, S He, ... Behavioural brain research 359, 737-748, 2019 | 66 | 2019 |
| Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma P Zhang, S Pei, L Wu, Z Xia, Q Wang, X Huang, Z Li, J Xie, M Du, H Lin Frontiers in endocrinology 14, 1196372, 2023 | 35 | 2023 |
| Anti-PD-(L) 1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges S Zhou, J Xie, Z Huang, L Deng, L Wu, J Yu, X Meng Cancer Letters 502, 166-179, 2021 | 24 | 2021 |
| PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy P Jin, J Li, Y Meng, L Wu, M Bai, J Yu, X Meng Cancer Letters 520, 91-99, 2021 | 17 | 2021 |
| Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and … L Wu, Z Zhang, M Bai, Y Yan, J Yu, Y Xu Cell Communication and Signaling 21 (1), 119, 2023 | 14 | 2023 |
| Efficacy of immune checkpoint inhibitors in patients with EGFR mutated NSCLC and potential risk factors associated with prognosis: a single institution experience M Bai, W Wang, X Gao, L Wu, P Jin, H Wu, J Yu, X Meng Frontiers in Immunology 13, 832419, 2022 | 13 | 2022 |
| Immunomodulatory role of azithromycin: Potential applications to radiation-induced lung injury Y Yan, L Wu, X Li, L Zhao, Y Xu Frontiers in Oncology 13, 966060, 2023 | 11 | 2023 |
| Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma Z Zhang, L Wu, J Li, J Chen, Q Yu, H Yao, Y Xu, L Liu Journal of Translational Medicine 20 (1), 602, 2022 | 9 | 2022 |
| Integrated analysis of EGFR mutated non‐small cell lung cancer reveals two distinct molecular subtypes M Bai, L Wu, M Zhao, P Jin, J Liu, W Wang, X Gao, Y Wang, W Chong, ... Clinical and Translational Medicine 13 (10), 2023 | 6 | 2023 |
| 18F-RGD PET/CT and Systemic Inflammatory Biomarkers Predict Outcomes of Patients With Advanced NSCLC Receiving Combined Antiangiogenic Treatment J Liu, L Wu, Z Liu, S Seery, J Li, Z Gao, J Yu, X Meng Frontiers in Oncology 11, 671912, 2021 | 6 | 2021 |
| Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and impedes lung cancer metastasis L Liu, X Chen, L Wu, K Huang, Z Wang, Y Zheng, C Zheng, Z Zhang, ... Experimental Hematology & Oncology 13 (1), 32, 2024 | 4 | 2024 |
| The efficacy and safety of Zengxiao Jiandu decoction combined with definitive concurrent chemoradiotherapy for unresectable locally advanced non-small cell lung cancer: a … L Wu, Y Zhu, X Yuan, Y Liu, Q Wu, Q Xu, M Hu, J Kang, J Fu, X Gong, ... Annals of Translational Medicine 10 (14), 2022 | 4 | 2022 |
| Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer L Wu, J Liu, S Wang, M Bai, M Wu, Z Gao, J Li, J Yu, J Liu, X Meng Frontiers in Endocrinology 13, 913631, 2022 | 4 | 2022 |
| Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy … L Ke, L Wu, J Yu, X Meng Nuclear Medicine Communications 42 (9), 1017-1023, 2021 | 4 | 2021 |
| Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study L Wu, B Cheng, X Sun, Z Zhang, J Kang, Y Chen, Q Xu, S Yang, Y Yan, ... MedComm 5 (3), e501, 2024 | 3 | 2024 |
| Efficacy and safety of local ablative therapy for patients with NSCLC and coexisting interstitial lung disease C Shao, X Zhi, S Mao, L Wu, J Yu, S Yang, W Wang, K Jia, L Luo, X Liu, ... Thoracic Cancer 15 (10), 778-787, 2024 | 1 | 2024 |
| HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung … L Liu, Z Zhang, C Jiang, Y Zhu, R Han, L Wu, Y Xu Aging (Albany NY) 16 (5), 4841, 2024 | 1 | 2024 |
| LINC01572 is a Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma Y Zheng, Z Zhang, X Li, L Wu, X Liu, L Liu, J Chen, D Wei Frontiers in Bioscience-Landmark 28 (10), 257, 2023 | 1 | 2023 |
| Identification and validation of a fatty acid metabolism gene signature for the promotion of metastasis in liver cancer Z Zhang, J Sun, C Jin, L Zhang, L Wu, G Tian Oncology Letters 26 (4), 1-13, 2023 | 1 | 2023 |
